Pfizer Business Development at a Glance

Last Modified Date: February 16, 2018

Pfizer dropped a bombshell when they announced their exit from the neuroscience field in January 2018. Everyone is wondering who will step up and fill Pfizer's Alzheimer's shoes, but what we're curious about is where Pfizer will direct their energy and resources to next.

They've struck two conservative deals so far in 2018: a gene therapy for amyotrophic lateral sclerosis with Sangamo, and selective protein degradation assets for "multiple disease areas" with Arvinas, which could mean anything from oncology to other rare disease targets.

Pfizer Stock

Pfizer Inc
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 19 992M
Therapeutic Focus: Biosimilars, Inflammation & Immunology, Metabolic Disease & Cardiovascular Risk, Oncology, Rare Diseases, Vaccines


DEAL ACTIVITY

Pfizer Data

Figure 1. Pfizer Inc. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)

Recent Deal Highlights:

COLLABORATION WITH ARVINAS FOR SMALL MOLECULES TARGETING DEGRADATION OF DISEASE CAUSING PROTEINS

Total Size: USD 830M | Therapeutic Area: Oncology | Date: January 2018

PRESS

COLLABORATION WITH SANGAMO THERAPEUTICS FOR ZINC FINGER PROTEIN GENE THERAPY

Total Size: USD 162M | Upfront: USD 12M | Therapeutic Area: Rare Diseases | Date: January 2018

PRESS

COLLABORATION WITH BASILEA PHARMACEUTICA FOR ANTIFUNGAL AZOLE

Total Size: USD 502M | Upfront: CHF 70M | Therapeutic Area: Other (Anti-infectives) | Date: June 2017

PRESS

R&D PIPELINE

Pfizer Pipeline

Figure 2. Pfizer Inc. R&D Pipeline at Present (February 2018)

Products from Recent Deals:

SANGAMO THERAPEUTICS PARTNERED GENE THERAPY

Disease Area: Rare Diseases | Status: Hemophilia A Phase II

ACQUIRED ANACOR'S NON-STEROIDAL CRISABOROLE

Disease Area: Inflammation & Immunology | Status: Morphea Phase II

PHILOGEN PARTNERED ANTIBODY-FUSED CYTOKINE DEKAVIL

Disease Area: Inflammation & Immunology | Status: Rheumatoid Arthritis with Methotrexate Phase II | Ulcerative Colitis Phase II

BUSINESS DEVELOPMENT TEAM


Business profiles tailored to your asset.